Hims 2-week deadline alert: hims shares decline amid lower revenue per order for glp-1 following novo nordisk collaboration termination, securities class action pending -- hagens berman

San francisco, aug. 13, 2025 (globe newswire) -- on august 5, 2025, investors in hims & hers health (nyse: hims) declined almost 11% in another sell-off after the company disclosed that it would lower revenue recognized per customer specific to its so-called personalized glp-1 component, a medication the company compounds to treat weight loss. this disclosure comes as the company previously experienced a sell-off in its shares which triggered a securities class action lawsuit tied to a cancelled collaboration with pharmaceutical giant novo nordisk to expand the availability of one of two fda-approved weight loss drugs -- wegovy® -- to patients.
HIMS Ratings Summary
HIMS Quant Ranking